PTO/SB/21 (08-00)

ease type a plus sign (+) inside this box -> +

TRANSMITTAL

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

09/826,609

April 5, 2001

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Application Number

Filing Dat

FORM		F: 1N 114	DODEDTO D	, , , , , , , , , , , , , , ,	VLD
i eti i ni i ni ni			ROBERTS, Bruc_ L		2002
(to be used for all correspondence after initial filing)		Group Art Unit	1642	00:00	2002
		Examiner Name	Karen A. Canella	TECH CENTER	1600/2900
Total Number of Pages in This Submission	3	Attorney Docket Number	GA0150C	12011	,
	ENCLO	OSURES (check all that apply)	***		j
Fee Transmittal Form	Assignment Papers (for an Application)		After Allowance Communication to Group		
Fee Attached	Drawing(s)		Appeal Communication to Board of Appeals and Interferences		
		ng-related Papers		Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)	
☐ After Final 2 Sheets ☐ Petition		1	Proprietary Information		
1 1 400 1 11 11 11 11 11 11 11 11		n to Convert to a onal Application	Status Letter		
		of Attorney, Revocation e of Correspondence Address	Other Enclosure(
	Terminal Disclaimer		Return Postc	ard	
Express Abandonment Request		st for Refund			
☐ Information Disclosure Statement ☐ CD, N		imber of CD(s)			
Certified Copy of Priority Document(s) Rea		rks			
Response to Missing Parts/ Incomplete Application					
Response to Missing Parts under 37 CFR 1.52 or 1.53					
SIGNAT	URE OF A	APPLICANT, ATTORNEY, O	R AGENT		
Elizabeth Lassen		· · · · · · · · · · · · · · · · · · ·			
,	Genzyme Corporation 15 Pleasant Street Connector				
Individual name P.O. Box 9322					
Framingham, Massa					
Signature Cly alu	th c	task			
	102				
	CE	RTIFICATE OF MAILING			` \
I hereby certify that this correspondence is	being depo	sited with the United States Pos	tal Service as first class	mail in an envelope	Ī
addressed to: Assistant Commissioner for	Patents, W	ashington, D.C. 20231 on this d	ate: October 1, 2002		1
Typed or printed name TARYN ANTAL	EK/				Ī
Signature / Mush	Wh	tlek	Date 10-0	01-02-)	J

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be send to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.





RECEIVED

OCT 0 9 2002

Patent

TECH CENTER 1600/2900

Our Docket: GA0150C

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
Roberts et al.

Serial No.: 09/826,609

Filed: April 5, 2001

For: GENES DIFFERENTIALLY EXPRESSED

IN CANCER CELLS TO DESIGN

CANCER VACCINES

Commissioner for Patents Washington, D.C. 20231

Art Unit: 1642

Examiner: Karen A. Canella

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST-CLASS MAIL IN AN ENVELOPE ADDRESSED TO: THE ASSISTANT COMMISSIONER FOR PATENTS, WASHINGTON, D.C. 20231

Octobel 1, 2002

Signature of person mailing correspondence

RESPONSE TO RESTRICTION REQUIREMENT

Sir:

This communication is being filed in response to the Restriction Requirement mailed September 13, 2002 in connection with the above-identified application.

Accordingly, this response is timely filed.

REMARKS

Claims 1-26 are pending in the subject application and are subject to a restriction requirement.

In the September 13, 2002 Office Action, the Examiner required restriction under 35 U.S.C. § 121 to one of the following allegedly independent and distinct inventions: